PKMYT1

Across TCGA pan-cancer cohorts, PKMYT1 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated PKMYT1 data layer compared with 5 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PKMYT1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PKMYT1 expression acts as an unfavorable survival marker, although some lineages such as THYM and STAD show a favorable association.

ACC, KIRP, and MESO are the cancer types where PKMYT1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.360	0.796	<.001	171	view →
KIRP	DFS	Median	All	0.771	0.932	<.001	138	view →
MESO	OS	Median	All	0.383	0.696	<.001	129	view →
KIRC	DFS	Median	All	0.753	0.852	<.001	118	view →
KICH	DFS	Tertile	III,IV	0.142	1.000	<.001	88	view →
LUAD	OS	Median	All	0.299	0.433	<.001	54	view →
LIHC	DFS	Median	All	0.454	0.628	<.001	53	view →
LGG	OS	Median	All	0.368	0.531	<.001	51	view →
SKCM	OS	Tertile	All	0.276	0.437	<.001	47	view →
CHOL	DFS	Median	II,III,IV	0.121	0.626	.002	43	view →
THCA	DFS	Quartile	III,IV	0.683	0.913	.002	37	view →
PAAD	DFS	Median	All	0.218	0.361	.009	22	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

PKMYT1–ACC (DFS)

Open the ACC breakdown →